146 related articles for article (PubMed ID: 38374817)
21. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
[TBL] [Abstract][Full Text] [Related]
22. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
[TBL] [Abstract][Full Text] [Related]
23. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy.
Moretz C; Cole AL; Mu G; Wu B; Guisinger A; Liu Y; Hahn B; Baylis L
Int J Chron Obstruct Pulmon Dis; 2020; 15():2207-2215. PubMed ID: 32982213
[TBL] [Abstract][Full Text] [Related]
25. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
Zheng J; Zhong N; Newlands A; Church A; Goh AH
Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
28. Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI.
Bogart M; Abbott CB; Bangalore M; McMorrow D; Packnett ER; DiRocco K
Int J Chron Obstruct Pulmon Dis; 2023; 18():2367-2379. PubMed ID: 37933243
[TBL] [Abstract][Full Text] [Related]
29. Real-World Disease Burden and Healthcare Resource Utilization Among Patients with COPD and Asthma Using Triple Therapy (FF/UMEC/VI) in the United States.
Igboekwe E; Verma S; Paczkowski R
Int J Chron Obstruct Pulmon Dis; 2024; 19():281-296. PubMed ID: 38292138
[TBL] [Abstract][Full Text] [Related]
30. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
Bansal S; Anderson M; Anzueto A; Brown N; Compton C; Corbridge TC; Erb D; Harvey C; Kaisermann MC; Kaye M; Lipson DA; Martin N; Zhu CQ; Papi A
NPJ Prim Care Respir Med; 2021 May; 31(1):29. PubMed ID: 34035312
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
Driessen MT; Whalen J; Seewoodharry Buguth B; Vallejo-Aparicio LA; Naya IP; Asukai Y; Alcázar-Navarrete B; Miravitlles M; García-Río F; Risebrough NA
Respir Res; 2018 Nov; 19(1):224. PubMed ID: 30458866
[TBL] [Abstract][Full Text] [Related]
32. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
Celli B; Crater G; Kilbride S; Mehta R; Tabberer M; Kalberg CJ; Church A
Chest; 2014 May; 145(5):981-991. PubMed ID: 24385182
[TBL] [Abstract][Full Text] [Related]
33. The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study.
Requena G; Dedman D; Quint JK; Ghosh RE; Williams R; Pimenta JM
Int J Chron Obstruct Pulmon Dis; 2021; 16():629-642. PubMed ID: 33731992
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.
Zhou Y; Duan S; Zhang L; Peng F
Respir Med; 2024 May; 226():107632. PubMed ID: 38621548
[TBL] [Abstract][Full Text] [Related]
35. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
Hahn B; Hull M; Blauer-Peterson C; Buikema AR; Ray R; Stanford RH
Respir Med; 2018 Jun; 139():65-71. PubMed ID: 29858004
[TBL] [Abstract][Full Text] [Related]
36. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
Hanania NA; Caveney S; Soule T; Tombs L; Lettis S; Crim C; Mannino DM; Patel H; Boucot IH
Int J Chron Obstruct Pulmon Dis; 2021; 16():1925-1938. PubMed ID: 34194225
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β
Czira A; Requena G; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():643-659. PubMed ID: 37155496
[TBL] [Abstract][Full Text] [Related]
38. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
[TBL] [Abstract][Full Text] [Related]
39. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
[TBL] [Abstract][Full Text] [Related]
40. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
Feldman G; Walker RR; Brooks J; Mehta R; Crater G
Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]